Please login to the form below

Not currently logged in
Email:
Password:

drug licensing

This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.

Roche makes protein degradation play with $135m Vividion deal

Roche makes protein degradation play with $135m Vividion deal

Roche has stepped up its interest in the emerging area of protein degradation as a drug target via a licensing deal with US biotech Vividion Therapeutics. ... Once again, that deal promises to unlock drug targets that have hitherto been considered

Latest news

More from news
Approximately 2 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    first launched on the world drug market than major companies (those with R&D spend of US$2bn). ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the

  • ‘Flexible working’: fashionable buzzword or fundamental business operation? ‘Flexible working’: fashionable buzzword or fundamental business operation?

    Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.

  • Charting a course for expansion Charting a course for expansion

    a key licensing agreement and the not inconsequential matter of a management reshuffle. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug

  • Pharma deals during January 2013 Pharma deals during January 2013

    Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    However, Sanofi has since discontinued its development. The company announced in May 2011 that the drug is available for licensing. ... The drug is also in phase III development for the acute treatment of VTE.

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Drivers of 2014′s Soaring Drug Approvals

    The FDA &EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future launch teams and some of the key areas of focus which could make or break a

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics